THE European Medicines Agency
is investigating findings by a group
of independent academic
researchers that suggest an
increased risk of pancreatitis and
pre-cancerous cellular changes
called pancreatic duct metaplasia in
patients with type 2 diabetes
treated with so-called GLP-1-based
therapies (glucagon-like peptide 1
(GLP-1) agonists and
dipeptidylpeptidase-4 (DPP-4)
inhibitors).
The research examination of a
small number of pancreatic tissue
samples obtained from organ
donors with and without diabetes
mellitus, who died due to causes
other than diabetes.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Mar 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Mar 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.